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ABSTRACT
The recent outbreak of the respiratory syndrome-related coronavirus (SARS-CoV-2) is stimulating 
an unprecedented scientific campaign to alleviate the burden of the coronavirus disease (COVID-
19). One line of research has focused on targeting SARS-CoV-2 proteins fundamental for its
replication by repurposing drugs approved for other diseases. The first interaction between the
virus and the host cell is mediated by the spike protein on the virus surface and the human 
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angiotensin-converting enzyme (ACE2). Small molecules able to bind the receptor-binding 
domain (RBD) of the spike protein and disrupt the binding to ACE2 would offer an important tool
for slowing, or even preventing, the infection. Here, we screened 2421 approved small molecules
in silico and validated the docking outcomes through extensive molecular dynamics simulations. 
Out of six drugs characterized as putative RBD binders, the cephalosporin antibiotic cefsulodin 
was further assessed for its effect on the binding between the RBD and ACE2, suggesting that it
is important to consider the dynamic formation of the heterodimer between RBD and ACE2 when 
judging any potential candidate.
1 INTRODUCTION
In early 2020, the severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) caused 
the spread of the coronavirus disease (COVID-19) on an unprecedented global scale. Symptoms
comprising smell and taste dysfunction[75], fever, cough, fatigue, headache and dyspnea[32]
usually appear after an average incubation period of just over 5 days[55], lasting for 6 to 41 
days[70]. The clinical picture is worsened by severe pneumonia with high levels of pro-
inflammatory cytokines[32] (a condition also known as “cytokine storm”), which triggers
extensive organ damage. SARS-CoV-2 is a positive-stranded RNA Betacoronavirus[41] in which 
about one-third of the genome codes for structural proteins such as envelope proteins, nucleocapsid 
proteins, membrane proteins and the spike (S) glycoprotein[23]. 
The S glycoprotein gives the characteristic “crown” shape to the coronaviruses phenotype, 
by forming prominent structures on the virion envelope, and drives virulence by mediating the first
interactions with the host cell[13] and inducing immune responses[34]. The trimeric S
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glycoprotein is composed of two subunits, S1 and S2, respectively mediating the binding to the
host cell and membrane fusion[1, 29]. Specifically, S1 comprises the receptor-binding domain 
(RBD, Figure 1a) for the angiotensin-converting enzyme 2 (ACE2), and stabilizes the prefusion 
state of the S2 subunit, which in turn drives the fusion of the viral particle into the host cell
membrane[66]. ACE2 is a type 1 membrane protein with an extracellular peptidase domain (PD) 
responsible for the maturation of the vasoactive hormone angiotensin[62]. Organs with high 
expression level of ACE2 are lungs, testis, heart, kidneys, and intestine[19, 42].
An intriguing way to tackle the SARS-CoV-2 infection is to disrupt the entrance of the
virus into host cells by blocking the molecular machinery implied in this fundamental step[37, 63, 
71, 74]. The structural basis of the interaction between ACE2 and the S glycoprotein RBD (Figure
1) could drive the discovery of small molecules and monoclonal antibodies[9, 53, 67] able to slow
down, or even prevent, the development of COVID-19[8, 28, 40, 76]. An ideal drug candidate
should selectively target the RBD without interacting with ACE2, to avoid possible side effects 
linked to angiotensin physiology[44, 56]. The S glycoprotein RBD binds to the α1 helix of the
ACE2 PD mainly through polar interactions (Figure 1b). Three different sites on RBD can be
distinguished (Figure 1b, Figure S3): site 1 (residues Q498, T500, N501, and Y505) and site 3 
(N487 and F486) interacts with ACE2 α1 helix C (residues Q24 and T27) and N (Y41, Q42, K353, 
and R357) termini, respectively. The RBD site 2 (residues R403, L455, F456, Y453, and Q493) 
interacts with the central segment of the α1 helix (D30, K31, H34, and D38).
Given the fast rate of diffusion of the pandemic, an outstanding number of drug repurposing 
campaigns have started[2]. The advantages of repurposing an “old” drug to treat new diseases
reside in the shorter development timelines and costs, due to the low-risk safety profile of already 
approved drugs[54]. In silico repurposing approaches usually rely on the virtual screening (VS) of 
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small drug databases, followed by a computational validation through molecular dynamics (MD) 
simulations to evaluate the stability of the predicted complexes in a flexible and fully hydrated 
simulated environment. Some examples of potential disruptors of the S glycoprotein interaction 
with ACE2, identified by simple molecular docking of approved drugs include hesperidin[73],
paritaprevir[45], cladribine, clofarabine, and fludarabine[15]. Differently, docking combined with 
MD simulations highlighted denopamine, bometolol, naminterol, rotigaptide, benzquercin[20], 
simeprevir, lumacaftor[64], tegobuvir, bromocriptine, baicalin[7], KT185, KT203, 
GSK1838705A, and BMS195614[10] as potential binders of the RBD. 
Assuming some redundancy between the libraries of compounds considered, the lack of 
consistency from different groups could be considered surprising. However, causes for this
discrepancy reside in the RBD coordinates used for VS, the different protocols for ligand 
preparation and docking, the number of MD replicas and the total amount of post-docking MD
sampling, the different force fields employed and the free-energy method used for rescoring 
binding modes. Here, we performed the VS of 2421 FDA-approved drugs against MD-derived 
coordinates of RBD. Post-docking MD simulations (in triplicate and up to 500 ns) of the top-
ranked 23 complexes highlighted six promising compounds, which were further evaluated 
according to the molecular mechanics energies combined with the generalized Born and surface
area continuum solvation (MMGBSA) energy. Cefsulodin, which stood out alongside Nilotinib as
a potential disruptor of the RBD – ACE2 interface, was then evaluated through supervised 
molecular dynamics simulations[16, 17, 58] (SuMD) aimed to reconstruct the binding event
between the RBD and ACE2. Overall, cefsulodin hindered the formation of the heterodimer. 
However, cefsulodin’s affinity for the RBD was affected by metastable interactions with ACE2, 
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indicating the importance of including the heterodimer during the screening of potential
candidates.
Figure 1. Supramolecular organization of the spike protein:ACE2 complex and the
RBD:ACE2 binding surface. a) Schematic representation showing the dimeric ACE2 protruding 
from the cytoplasmic membrane and acting as receptor for the trimeric SARS-CoV2 spike protein
in prefusion open conformation, which binds through one of the three available RBD in up 
position. b) two side-views of the contact interface between the RBD (orange) and ACE2 (purple). 






          
  
 
         
      
     
       
       
       
        
  
     
      
        
         
        
    
      
2. METHODS
The sequential steps of the computational protocol followed in the present work (Figure S1) are
here described.
2.1 Classic molecular dynamics simulation of the spike protein RBD
The coordinates of a monomer of the spike protein (S protein) RBD were retrieved from PDB 
entry 6M17[76], which reports the pre-fusion open conformation of the trimeric S protein (one
RBD in up position) in complex with one monomer of ACE2. Only residues C336-F515 from one
monomer of the S protein were considered. After removing the N-acetylglucosamine residues
(which are not located in the RBD pocket[8]), hydrogen atoms were added using pdb2pqr[18] and 
the propka[51] software. The resulting system was prepared for simulations with the
Amber14SB[46] force field by creating a 90 Å x 92 Å x 73 Å TIP3P[36] solvated box. Overall
charge neutrality was maintained by adding two Cl- ions. 
ACEMD[27] was used for both equilibration and 200 ns of MD productive simulation. 
Restraints were applied to protein alpha carbon atoms and gradually released throughout 2 ns of 
equilibration before starting the MD production. Productive trajectories (Table S4) were computed 
with an integration time step of 4 fs in the canonical ensemble (NVT). The target temperature was
set at 300 K, using a thermostat damping of 0.1 ps-1; the M-SHAKE algorithm[24, 39] was 
employed to constrain the bond lengths involving hydrogen atoms. The cut-off distance for 
electrostatic interactions was set at 9 Å, with a switching function applied beyond 7.5 Å. Long 
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range Coulomb interactions were handled using the particle mesh Ewald summation method 
(PME)[22] by setting the mesh spacing to 1.0 Å.
The 200 ns trajectory was clustered into 10 groups of frames using the VMD plugin 
Clustering (at <https://github.com/luisico/clustering), according to the RMSD of the residues
delimiting the RBD pocket (residues Y453, R403, and K417) with respect to the starting 
conformation. A visual inspection of the trajectory revealed that the breathing of the RBD pocket
was primarily due to side chain movements. R403 and K417, in particular, heavily contributed to 
shaping the pocket because the side chains are longer than those of other neighboring residues. 
Moreover, position 417 is occupied by valine in the SARS-CoV RBD, indicating a potential
element of resistance or selectivity for drug candidates. The frame from the most populated cluster 
with the highest RMSD value (representative for a “relaxed” and more open conformation of the
pocket) was extracted and used for the subsequent steps. This double criterion should allow
selection of a structure quite close to the RBD average conformation, taking into account also the
possible induced-fit produced by ligand binding, which might favor a more open pocket state.
The RBD from both PDB 6M17 and the MD frame were used as input for the FTMap [4, 38]
and DeepSite [35] webservers to evaluate the RBD binding site before and after the MD simulation 
of RBD (Figure S2). As shown in Figure S2, the binding pocket is larger in the MD structure than
in the RBD structure from PDB 6M17
2.2 Virtual Screening of the approved compounds library
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The RBD from the MD frame was used to dock an SDF library of FDA-approved drugs[14]
(available at https://www.selleckchem.com/screening/fda-approved-drug-library.html). 
RDKit (https://www.rdkit.org/) was used to remove organometallic compounds and entries with 
more than 12 rotatable bonds, strip counterions from salt molecules, and generate initial 3D
conformations. The resulting database was further processed through Chimera[52] and Open 
Babel[50] to check the protonation state of the compounds, assign MMFF94[26] partial charges
and generate final pdbqt files for the 2421 structures.
Docking simulations were performed employing AutoDock Vina[65] within a cubic 25 Å 
x 25 Å x 25 Å volume centered at the oxygen atom of the Y495 side chain, therefore focusing on 
the main RBD pocket shown in Figure S2b. Ten conformations for each run were generated.
2.3 Post Docking molecular dynamics simulations
The 23 compounds (Table S1) with the best docking scores were prepared for classic MD with 
the Amber14SB[46]/GAFF[68, 69] force field by creating a 77 Å x 95 Å x 71 Å TIP3P[36]
solvated box (a padding of 15 Å along the x, y, and z dimensions was considered). Overall charge
neutrality was maintained by adding Cl- or Na+ counterions. ACEMD[27] was used for both 
equilibration and three replicas of duration 100 ns each. Restraints were applied to protein alpha
carbon atoms and gradually released throughout 2 ns of equilibration before starting the MD
production replicas.
After 100 ns, the RMSD of the compounds with respect to the docking pose was calculated 
with VMD[33] after aligning the RBD alpha carbon atoms to the initial conformation. The MD
replicas in which the final ligand RMSD was lower than 7 Å were extended to 500 ns, for a total
8
  
        
        
    
       
      
       




          
        
      
        
       
         
        
  
      
      
 
of 13 replicas involving 9 compounds (Table S1). The RMSD of the drugs was then computed 
again, highlighting the compounds still bound to the RBD pocket (Table S1): cefsulodin, 
cromoglycate, nafamostat, nilotinib, penfluridol, and radotinib.
For these six compounds, the binding energies were evaluated by computing the molecular 
mechanics energies combined with the generalized Born and surface area continuum solvation 
were computed with the MMPBSA.py [47] script, from the AmberTools17 suite (The Amber 
Molecular Dynamics Package, at http://ambermd.org/) employing the default settings and 
considering the last 50 ns of simulations out of 500 ns (1 frame every 100 ps of the simulation).
2.4 Classic MD simulations of ACE2:RBD complex
The coordinates of the spike protein RBD (residues C336-F515 from one monomer of the S
protein) and human ACE2 (residues I21-N599) were retrieved from one monomer present in the
PDB entry 6M17[76]. After removing the N-acetylglucosamine residues (which are not located at
the interface between the proteins) and the zinc ion, hydrogen atoms were added using pdb2pqr[18]
and the propka[51] software. The resulting system was prepared for simulations with the
Amber14SB[46] force field by creating a 124 Å x 117 Å x 160 Å TIP3P[36] solvated box (a
padding of 15 Å along the x, y, and z dimensions was considered). Overall charge neutrality was
maintained by adding 21 Na+ ions. 
ACEMD[27] was used for both equilibration and 200 ns of MD productive simulation. 
Restraints were applied to protein alpha carbon atoms and gradually released throughout 2 ns of 
equilibration before starting the MD production. 
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MMGBSA binding energies were computed as described in Section 2.3 considering 1000 
frames (1 frame every 200 ps of the simulation).
2.5 Supervised MD simulations of the ACE2:RBD complex
The supervised molecular dynamics (SuMD) is an adaptive sampling method for speeding up 
the simulation of binding[16, 58] and unbinding processes[3, 17]. Sampling is gained without the
introduction of any energetic bias, by applying a tabu–like algorithm to monitor the distance
between the centers of mass (or the geometrical centers) of the ligand and the predicted binding 
site or the receptor. However, the supervision of a second metric of the system can be
considered[3]. A series of short unbiased MD simulations are performed, and after each 
simulation, the distances (collected at regular time intervals) are fitted to a linear function. If the
resulting slope is negative (for binding) or positive (for unbinding) the next simulation is started 
from the last set of atom velocities and coordinates, otherwise, the simulation is discarded and a 
new one is started from the last productive coordinates by randomly assigning the atomic
velocities. 
The RBD (residues C336-F515 from one monomer of the S protein) and ACE2 (residues I21-
N599) from one monomer present in the PDB entry 6M17[76] were placed about 25 Å away from
each other and prepared for simulations as reported in section 2.1. Restraints were applied to 
protein alpha carbon atoms and gradually released throughout 2 ns of equilibration before starting 
the MD production simulation. Four SuMD replicas were collected by monitoring the distance
between the centroid of RBD residue Q493 and the centroid of ACE2 residues K31, E35, 
throughout successive 2 ns-long windows. In the PDB structure 6M17, the interactions between 
Q493 (RBD) and K31, E35 (ACE2) are in a central position at the interface between proteins. The
10
  
       
 
     
 
  
       
       
      
     
      
        
 
      
      




      
 
supervision was iterated until the distance was lower than 7 Å, then 200 ns of classic
(unsupervised) MD was performed.
MMGBSA binding energies were computed as described in Section 2.3 considering 1 
frame every 100 ps of the simulation.
2.6 SuMD simulations of the RBD:cefsulodin:ACE2 ternary complex
The RBD:cefsulodin complex resulting from the post docking MD (500 ns, section 2.4) was
placed about 25 Å away from ACE2 (residues I21-N599). The resulting system was prepared for 
simulations as reported in section 2.4. In analogy with SuMD simulations in the absence of 
cefsulodin bound to RBD (section 2.6), four SuMD replicas were collected by monitoring the
distance between the centroid of RBD residue Q493 and the centroid of ACE2 residues K31, E35, 
throughout successive 2 ns-long windows. The supervision was iterated until the distance was
lower than 7 Å, then 200 ns of classic (unsupervised) MD was performed.
Molecular mechanics energies combined with the generalized Born and surface area
continuum solvation were computed with the MMPBSA.py [47] script, from the AmberTools17 
suite (The Amber Molecular Dynamics Package, at http://ambermd.org/) employing the default
settings and considering 1 frame every 100 ps of simulation.
3 RESULTS AND DISCUSSION
3.1 Virtual screening and post-docking molecular dynamics simulations suggest putative
SARS-CoV-2 RBD binders amongst FDA-approved drugs
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Virtual screening (VS) of approved compounds represents the first step of drug repurposing 
strategies in the pursuit of candidates able to target SARS-CoV-2. Amongst the viral proteins that
could be therapeutically exploted[25, 73], targeting the S glycoprotein could represent a promising 
way to treat and, most importantly, prevent COVID-19. Indeed, the ACE2:RBD binding interface
(Figure 1), partially overlaps a pocket (Figure S2) that can be targeted with small molecules to 
disrupt the early stage of SARS-CoV-2 infection. 
The use of MD structures, instead of cryo-EM or crystal structures, can enhance the
docking predictivity[48] thanks to the relaxation of the system from the solid phase to the fully 
hydrated one and the inclusion of full molecular flexibility. Extracting the RBD coordinates from
the cryo-EM structure of the RBD-ACE2 complex (PDB 6M17) and processing the RBD through 
MD simulations allowed the RBD pocket to expand (Figure S1a,b) and to expose residues located 
within site 2 (Figure S1c,d). On this optimized structure, we docked 2421 approved drugs. The 23 
top-ranked compounds from the VS (Table S1) were subjected to three MD replicas to validate
the stability of the predicted complexes. Performing MD simulations from docking poses
represents a valuable approach for evaluating the stability of docking-predicted complexes in a
fully hydrated and flexible environment, therefore overcoming well-known limits of molecular 
docking[59]. 
Notably, none of these 23 drugs remained bound to RBD in all the three MD replicas (Table
S1). The best-ranked compound according to Autodock, dihydroergotamine, completely 
dissociated during one replica, and moved away in the other two replicas, transiently interacting 
with other regions of the RBD (final RMSDs with respect to the docked pose were 25.6 Å and 
14.5 Å respectively). The second-ranked compound, nilotinib, displayed good stability with slight
conformational rearrangement throughout the three MD simulations (final RMSDs with respect to 
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the docked pose 3.5 Å, 3.8 Å and 5.4 Å respectively). Cefsulodin and cromoglycate remained 
stably bound during two MD replicas out of three, while fluralaner, nafamostat, naringin, 
penfluridol, radotinib, and regorafenib were stable during one replica (Table S1). 
The 13 simulations characterized by good stability were extended to 500 ns for further 
evaluating the stability of the complexes. Fluralaner, naringin, and regorafenib dissociated from
the RBD (final RMSD with respect to the docked pose 14.4 Å, 11.8 Å and 12.4 Å, respectively). 
Six compounds, on the other hand, remained bound: cefsulodin, cromoglycate, nafamostat, 
nilotinib, penfluridol, and radotinib (Table S1, Figure S3a). MMGBSA binding energies (Table
S1, Figure 3Sb) indicated nilotinib and cefsulodin as the most stable ligands (-53.2 ± 4.1 kcal/mol
and -41.3 ± 6.7 kcal/mol, respectively), while the other compounds displayed a similar MMGBSA
binding energy (e.g. values close to -30 kcal/mol). A comparison of the last frames from the six 
500 ns MD simulations reveals similarities and differences in the conformations of the bound 
ligands and the RBD (Figure 2a). Direct interactions with cromoglycate and nafamostat, for 
example, folded RBD site 3 towards the putative binding pocket occupied by the ligand. As a
general view, the six compounds occupied a pocket region partially overlapping RBD site 1 and 
site 2, and formed four main groups of interactions with the protein (Figure 2b). Within RBD site
1, the ligands formed hydrophobic p-p interactions with the side chain of Y505 and hydrogen 
bonds with the hydrophilic region in the proximity of backbone and the side chain of N501. Site
2, instead, stabilized the ligands through a mix of hydrophobic interactions deep in the pocket and 
hydrogen bonds with residues on the surface of the binding site (which is comprised of R403, 
K417, Y453, and G496).
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3.2 Cefsulodin, cromoglycate, nafamostat, nilotinib, penfluridol and radotinib proposed
binding modes
Cefsulodin (Figure 2c) is a third-generation b-lactam cephalosporin antibiotic with a spectrum
of activity restricted to Pseudomonas aeruginosa and Staphylococcus aureus[49]. Interestingly, 
during the 500 ns MD simulation, cefsulodin rapidly dissociated from the starting docked pose
before rebinding the RBD pocket after 100 ns with a different stable conformation (MMGBSA
binding energy -41.3 ± 6.7 kcal/mol, Table S1), Figure S3a, Video S1). In this binding mode, the
drug formed hydrogen bonds with G502, G496, R403, and K417, and hydrophobic contacts with 
Y505, K417, I418, Y453, and Y495 side chains (Figure 2c, Video S1). 
Interestingly, the other cephalosporins that were docked all obtained modest scores. The
analog closer to cefsulodin in term of docking results was cefonicid (docking score = -7.0 kcal/mol, 
Figure S4). A direct comparison between cefsulodin, cefonicid and cefazolin (a further b-lactam 
cephalosporin, modest docking score of -6.2 kcal/mol, Figure S4) shows how different structures
affected docking results: cefsulodin and cefonicid, indeed, bear a terminal phenyl ring which 
appeared to drive a common docking pose, while cefazolin’s tetrazole moiety produced a divergent
flipped predicted conformation (Figure S4). 
Cromoglycate (Figure 2d) is an anti-inflammatory drug indicated for the prevention of 
acute episodes in patients with mild to moderate asthma. During the 500 ns post-docking MD
simulation cromoglycate experienced remarkable fluctuations within the binding site (Figure S3, 
Video S2) before forming interactions with residues that are part of RBD site 3 (i.e. G482, Figure
2d, Figure 2a, Video S2). The drug formed two persistent hydrogen bonds between the
14
  
      
 
         
        
    
        
       
       
 
        
        
        
         
   
     
      
     
 
         
      
      
    
carboxylates and N501, Y453 side chains (Figure 2d). Hydrophobic interactions involved Y505, 
Y495, and Y453 (Figure 2d).
Nafamostat (Figure 2e) is a serine protease inhibitor currently in clinical trials for SARS-
CoV2 infection in the light of its proposed ability to inhibit the transmembrane protease serine 2 
(TMPRSS2)-dependent host cell entry[30, 31]. During our simulation (Video S3) nafamostat
remained bound to the RBD pocket thanks to hydrogen bonds between the guanidinium group and 
N501, G502 and G496 (Figure 2e), as well as hydrophobic contacts with Y505 (MMGBSA
binding energy = -29.8 ± 3.9). Transient interactions were formed between the molecule and the
RBD site 3, in particular the Y489 side chain (Figure 2e, Video S3).
Nilotinib (Figure 2f) is a tyrosine kinases inhibitor with antineoplastic activity. In has been 
proposed to act in two different stages of the coronavirus infection cycle: in the early phases of 
infection, it has been proposed to inhibit the virion fusion with the endosome1, while at a later 
stage it has been proposed to inhibit the viral replication[60] via ABL-mediated cytoskeletal
rearrangement[12, 21]. During the 500 ns MD simulation (Video S4), nilotinib, which remained 
stably bound to the RBD pocket (MMGBSA binding energy = -53.2 ± 4.1 kcal/mol), positioned 
the trifluoromethyl group deep in the binding pocket and formed hydrophobic interactions with 
I418, Y495, F497, Y505, and the alkyl chain of R403 (Figure 2f, Video S4). Hydrogen bonds were
established between the drug and the N501 and R403 side chains (Figure 2f, Video S4).
Penfluridol (Figure 2g) is a long-acting antipsychotic agent[11]. During the 500 ns MD
simulation (Video S5) the drug was anchored to the RBD through interactions between the
piperidin-4-ol group and residues D406, Y453 (Figure 2g, Video S5), while the flexible bis(4-
fluorophenyl)butyl and 4-chloro-3-(trifluoromethyl)phenyl moieties explored several
15
  
      
 
       
       
       
      
   
   
      
     
          
          
       
          
        
     
      
      
       
 
 
conformations. Notably, penfluridol shares the phenylpiperidin-4-ol scaffold with the SARS-CoV
inhibitor K22[43], which may indicate a common molecular mechanism.
Radotinib (Figure 2h) is a second-generation BCR-ABL tyrosine kinase inhibitor with 
therapeutic indication for patients resistant or intolerant to imatinib[5]. Despite the high structural
similarity with nilotinib (from which it differs only by the pyridine terminal ring, Figure 2f,h) and 
the good interaction network within the RBD pocket (hydrogen bonds with R403 and Y453 side
chains, hydrophobic interactions with Y505, I418, and Y495, Figure 2h), radotinib displayed lower 
stability (MMGBSA binding energy = -28.6 ± 3.8) and higher conformational fluctuation (Video 
S6) than nilotinib. The reason for this could reside in the different conformations predicted by 
docking (Figure S5). Indeed, the nilotinib top-ranked pose oriented the trifluoromethyl group 
toward the inner side of the pocket, while radotinib’s best pose was predicted to be almost planar 
on the pocket surface. This binding mode of radotinib did not evolve towards more stable states
during the MD simulation (e.g. it did not reorient the trifluoromethyl group), resulting in sub-
optimal interactions with the RBD. The different outcomes from almost identical ligands
highlights the importance of the docking pose choice. The common practice to pick the top-ranked 
pose can lead to overlooking other suitable conformations that are penalized by lower docking 
scores computed without considering the explicit solvent contribution to the binding. However, 
the MD post-processing of docking poses can be time-consuming, and therefore applicable only 








      
         
       
        
        
     
       
         
       
         
 
 
    
  
     
        
      
     
        
       
       
Figure 2. Binding conformation of cefsulodin, cromoglycate, nafamostad, nilotinib, 
penfluridol, and radotinib after 500 ns of post-docking MD simulations. a) comparison 
between the last MD frames highlighting the different RBD orientation; cromoglycate and 
nafamostat strongly affected the RBD site 3. b) schematic representation of the interaction features
characterizing the RBD pocket as determined by the binding modes of the six proposed ligands;
the three sites responsible for binding ACE2 are indicated with dashed lines (site 1 in red, site 2 in 
blue, and site 3 in green respectively). c-h) binding modes of the ligands after 500 ns of post-
docking classic MD. Hydrogen bonds are shown as dashed red lines, while hydrophobic contacts
are depicted as transparent cyan surfaces. The 2D structures of the compounds are reported for 
clarity. c) cefsulodin; d) cromoglycate: e) nafamostat; f) nilotinib; g) penfluridol; h) radotinib. The
three RBD sites responsible for binding ACE2 are indicated with superscripts on the RBD residue
names (S1, S2, and S3).
3.3 Simulating the RBD:ACE2 binding mechanism to retrieve insights into the effect of 
potential disruptors
During post-docking MD simulations, putative binders of the RBD interacted with protein 
residues that are responsible for direct contacts with ACE2 (Figure 1, Figure 2). Cefsulodin and 
nilotinib, for example, made stable contacts with residues located on both RBD site 1 (Y505, N501, 
G502, and F497) and site 2 (L455, Y495 and G496) that contributes to the stabilization of the
complex with ACE2 (Table S2). This indicates the potential ability of these drugs to disrupt key 
interactions of the SARS-CoV-2 spike protein. To further test this hypothesis, we simulated the
binding between the RBD and ACE2 in the absence of any small molecule or in presence of 
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cefsulodin bound to RBD (conformation sampled after 500 ns of post-docking MD, Figure 2c). 
We focused on cefsulodin rather than nilotinib in the light of the spontaneous re-binding event
observed during the simulation (Video S1, Figure S3), the numerous hydrogen bonds formed with 
the RBD (Figure 2c), and the low toxicity[72].
The first batch of SuMD simulations sought to reproduce a putative binding path of the
RBD:ACE2 hetero dimer (PDB 6M17). In one out of four replicas, the RBD was able to bind in 
close agreement with the experimental conformation reported in the PDB structure 6M17 (Video 
S7, Figure 3a,b). A further SuMD replica reproduced the complex with good agreement to the
cryo-EM structure (Figure S6a), while two other simulations were not productive after 230 ns
(Figure S6b,c). SuMD reproduced the stability and intermolecular contacts observed between the
RBD and ACE2 during MD of the PDB structure 6M17 (Figure 3a,b), highlighting RBD site 1 
residues T500, Y505, N501, and Q498 as the most involved in interactions alongside Q493, L455, 
K417 (site 2) and F486 (site 3)[6, 61, 64].
These data represented a robust reference for evaluating the potential effect of a ligand on 
the formation of the RBD:ACE complex. We then performed four SuMD replicas to study the
binding between the RBD in complex with cefsulodin and ACE2 (Video S8, Video S9, Figure
3c,d, Figure S7). During two simulations, the RMSD of the RBD with respect to the experimental
conformation increased, indicating non-productivity of the simulated binding event due to 
stochastic reasons (e.g. the supervision on the distance between the RBD residue Q493 and the
ACE2 residues K31 and E35 failed to move the proteins closer), rather than the presence of 
cefsulodin (Figure S7). The other two replicas, instead, were characterized by RMSD values
decreasing to a plateau of about 10-15 Å (Figure 3c,d), consistent with a possible productive
contact between the proteins. In one of the two productive SuMD simulations (Video S8, Figure
19
  
     
    
       
     
      
        
   
       
      
    
       
       
      
       
         
 
       
         
    
     
 
 
3c), despite the formation of a ternary complex involving the RBD, cefsulodin and ACE2, the
MMGBSA binding energy between the RBD and ACE2 oscillated around zero, indicating the
formation of a sub-optimal binding interface between the two proteins (Figure 3c). Following a
slight conformational rearrangement, cefsulodin remained bound to the interface between proteins
for the whole simulation (MMGBSA binding energy in the -20 to -40 kcal/mol range, Figure 3c, 
cf. MMGBSA binding energy in the range of -32 to -50 kcal/mol in Figure S3). The RBD formed 
limited contacts with ACE2 (residues D38, Y41, and K353, Figure 3c) through Y449 and Q498 
(site 1), and Q494 (site 2) side chains. A divergent scenario was sampled during the other 
productive SuMD replica (Video S9, Figure 3d). During this simulation, cefsulodin was displaced 
by ACE2 after 140 ns, allowing the formation of a metastable binary complex between RBD and 
ACE2 (RBD –ACE2 MMGBSA binding energy » -20 kcal/mol, against » -45 kcal/mol as
computed for the experimental complex, Figure 3a,b); RBD residues F486, N487, S477 (site 3), 
Y489 Q493 (site 2), and T449 (site 1) were highly involved. Despite the displacement of 
cefsulodin, the RBD did not reach the experimental conformation over the simulated 230 ns
(RMSD » 10-15 Å). However, over a longer timescale, it is plausible that the RMD eventually 
would rearrange to the fully bound conformation.
Taken together, these results suggest that a compound selected through VS and post-
docking MD simulations may be less effective when the dynamic of protein-protein formation is
taken into account. SuMD (and other adaptive or enhanced MD sampling methods) may represent
a further step in silico to the identification of protein-protein interaction (PPI) disruptors that may 






         
       
         
      
  
        
        
        
    
         
   
     
         




       
  
   
       
  
Figure 3. Influence of RBD-bound cefsulodin on the intermolecular recognition between
RBD and ACE2 during binding. Top panels plots show the RMSD with respect to PDB 6M17 
of the whole RBD (cyan line) and the RBD residues located at the binding interface with ACE2 
(green line), respectively; the red and black lines indicate the MMGBSA binding energy of 
RBD:ACE2 complex and cefsulodin, respectively. Bottom panels: RBD:ACE2 intermolecular 
contacts potted on the surface of the proteins; the RBD pocket, which was occupied by cefsulodin 
at the beginning of the simulations, is indicated in green in c and d. a) classic MD simulation of 
the RBD:ACE2 complex from PDB 6M17; b) RBD:ACE SuMD binding; the dimer reached the
6M17 bound conformation (RMSD » 2 Å) in less than 20 ns. c) ) RBD:cefsulodin:ACE ternary 
complex SuMD binding replica 1; despite reaching the ACE2 surface, RBD was not stabilized due
to the co-presence of cefsulodin on protein interfaces; d) RBD:cefsulodin:ACE2 ternary complex 
SuMD binding replica 2; cefsulodin was displaced by ACE2 after 140 ns of simulation, However, 
the RBD did not reach the experimental conformation within 230 ns (RMSD » 10-15 Å). ). Vertical
dashed lines indicate the start of 200 ns of classic MD after SuMD; the three RBD sites responsible
for binding ACE2 are indicated with superscripts on the RBD residue names (S1, S2, and S3).
4 CONCLUSION
We performed the VS and extensive MD and SuMD simulations of FDA-approved drugs. 
According to our computational protocol, six compounds (cefsulodin, cromoglycate, nafamostat, 
nilotinib, penfluridol, and radotinib) are predicted to bind the SARS-CoV-2 S glycoprotein RBD. 
Cefsulodin (a cephalosporin antibiotic) and nilotinib (a kinases inhibitor) were the most efficient
binders in silico. 
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We further evaluated cefsulodin as a potential disruptor of the RBD:ACE2 complex by 
simulating the binding process in the absence and presence of the drug bound to the RBD. While
cefsulodin hindered the formation of the complex in the simulated conditions, it also appears that
ACE2 altered the affinity of cefsulodin for the RBD. According to SuMD, the presence of 
cefsulodin in the RBD pocket during the approach to ACE2 could modify the overall binding path 
between the two proteins, hampering the formation of the experimental arrangement observed in 
the cryo-EM structure. This is promising for the success of drug repurposing strategies targeting 
the early step of SARS-CoV-2 infection. However, our simulations suggested also the alternative
scenario in which the dynamic protein-protein interface formed during the binding between RBD
and ACE2 creates a supramolecular environment that modifies the affinity of the putative disruptor 
for the RBD pocket, with the final effect of partially or completely displacing it. This double
outline raises the question whether disruptors should be in silico designed considering only 
complementarity and affinity for the RBD pocket or designed to stabilize unproductive metastable
ternary complexes (e.g. involving the RBD, ACE2 and the ligand). Future work will aim to 
compare several other potential RBD binders (i.e. nilotinib) to deliver insights about what set of 
interactions with the RBD are more prone to stabilize the ligand during the ACE2 recognition.
If repurposing strategies fail to deliver an actual disrupter of the protein, it would be
necessary to further investigate the binding process between the spike protein and ACE2, 
characterizing intermediate complexes that could be drugged to prevent the formation of the one
which is productive for the cell invasion. These results extend the computational toolkit for the
rational discovery of PPIs disruptors to adaptive or enhanced sampling methods, like SuMD, able
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